Patents Examined by Hasan Ahmed
  • Binding proteins to the constant region of immunoglobulin G
    Patent number: 9493547
    Abstract: The present invention provides polypeptides that bind to immunoglobulin G and methods for their use.
    Type: Grant
    Filed: March 25, 2013
    Date of Patent: November 15, 2016
    Assignee: University of Washington Through its Center for Commercialization
    Inventors: David Baker, Eva-Maria Strauch, Sarel Jacob Fleishman
  • Surface-modified heavy metal nanoparticles, compositions and uses thereof
    Patent number: 9486480
    Abstract: Surface-modified heavy metal nanoparticles, including a heavy metal core and a coating layer, the coating layer having at least one ligand, conjugated to polyethylene glycol, the at least one ligand is selected from N-acetyl cysteine, albumin, cysteine, methionine, glutathione, amino thiols, thio-carboxylic acids, ammonia, amines, diamines or any combination thereof. Compositions including surface-modified heavy metal nanoparticles and uses thereof in treatment and diagnosis of various conditions.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: November 8, 2016
    Assignee: METALLO THERAPY LTD.
    Inventors: Amal Ayoub, Nassim Safadi, Sobhi Basheer
  • Peptidomimetics possessing photo-controlled biological activity
    Patent number: 9481712
    Abstract: The present invention relates to pharmaceutically and/or diagnostically active compounds, in particular peptide analogs (peptidomimetics), which can be reversibly controlled between an active and an inactive state by irradiation with light of different wavelengths. The present invention further relates to an intermediate compound usable in the manufacture of such pharmaceutically and/or diagnostically active compounds, as well as a manufacturing method thereof.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: November 1, 2016
    Assignees: Karlsruher Institut Für Technologie, National Taras Shevchenko University
    Inventors: Sergiy Afonin, Oleg Babii, Igor Komarov, Pavlo Mykhailiuk, Anne Ulrich
  • Hexadepsipeptide analogues as anticancer compounds
    Patent number: 9475842
    Abstract: This invention relates to an isolated compound of Formula (1) or derivatives or pharmaceutically acceptable salts thereof. The invention also includes all isomeric and tautomeric forms of the compound of Formula (1) or the derivatives thereof. The present invention further relates to processes for the production of the compound of Formula (1) by fermentation of the fungal strain of Actinomycetes (PM0895172/MTCC 684), pharmaceutical compositions comprising the compound of Formula (1) as the active ingredient; and use of the compounds or composition containing them in the treatment of cancer.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: October 25, 2016
    Assignee: Piramal Enterprises Limited
    Inventors: Prabhu Dutt Mishra, Sreekumar Sankaranarayanan Eyyammadichiyl, Saji David George, Shailendra Sonawane, Narayan Subhash Chakor, Abhijit Roychowdhury, Rajiv Sharma
  • Methods for treatment of nephrotic syndrome and related conditions
    Patent number: 9475850
    Abstract: The present disclosure provides a method for treating and/or preventing a condition characterized as a nephrotic syndrome, such as but not limited to minimal change disease (MCD) and membranous nephropathy (MN), and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein. Such methods comprise the therapeutic delivery of an Angptl4 polypeptide or Angptl4 polypeptide derivative to a subject.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: October 25, 2016
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventor: Sumant S. Chugh
  • Engineered potent cytotoxic stapled BH3 peptides
    Patent number: 9464125
    Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: October 11, 2016
    Assignee: The Trustees of Princeton University
    Inventors: A. James Link, Siyan Zhang
  • Hydrogels with release element
    Patent number: 9457123
    Abstract: An adhesive hydrogel dressing as well as methods of applying the dressing to a patient. The dressing generally comprises an adhesive hydrogel pad, a backing layer, and an adhesive layer on the backing layer facing the hydrogel pad. The adhesive layer and backing layer form a perimeter around the hydrogel pad and hold the hydrogel pad in place on an application surface. A release element is in contact with at least a portion of the edge of the hydrogel pad proximate the area that the hydrogel pad and release liner separate during liner removal.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: October 4, 2016
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: David R. Holm, Scott A. Burton, Robert A. Asmus, Richard L. Jacobson
  • Poly(vinyl benzoate) nanoparticles for molecular delivery
    Patent number: 9433581
    Abstract: The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC50>1000 ?g/mL) and primary bovine primary aortic endothelial cells (IC50>500 ?g/mL), and exert non-observable bactericidal activity against a selection of representative test microbes (MIC>250 ?g/mL).
    Type: Grant
    Filed: May 20, 2013
    Date of Patent: September 6, 2016
    Assignee: University of South Florida
    Inventors: Edward Turos, Raphael Labruere, Ryan Scott Cormier, Renaud Sicard
  • Controlled release compositions for modulating free-radical induced damage and methods of use thereof
    Patent number: 9427472
    Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: August 30, 2016
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Fragrance sampler insert
    Patent number: 9399081
    Abstract: A fragrance sampler is provided which is made from two plies, a bottom ply and a top ply, of material. A cosmetic, such as a wet fragrance, sample is deposited on the bottom ply. A well is formed in at least one of the plies and is sized and shaped to surround the sample. The two plies are then adhered together to form a liquid tight seal between the two plies and around the well.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: July 26, 2016
    Assignee: Orlandi, Inc.
    Inventor: Sven Dobler
  • Osmotic drug delivery system
    Patent number: 9393203
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: July 19, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • Oxidatitive photoactivated skin rejeuvenation composition comprising hyaluronic acid, glucosamine, or allantoin
    Patent number: 9375446
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 28, 2016
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Modified starch derivative-based matrix for colon targeting
    Patent number: 9358205
    Abstract: A controlled-release oral pharmaceutical composition of at least an active agent, including: a) a lipophilic matrix consisting of lipophilic compounds and/or amphiphilic compounds; and b) an hydrophilic matrix, wherein the hydrophilic matrix includes at least an indigestible polysaccharide, the active ingredient being dispersed in the lipophilic and/or the hydrophilic matrix. The present invention also relates to a process for the preparation of such a pharmaceutical composition.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: June 7, 2016
    Assignee: Roquette Freres
    Inventors: Olaf Haeusler, Marie-Helene DeGrave, Daniel Wils, Stefanie Krenzlin, Juergen Siepmann
  • Timed, sustained release systems for propranolol
    Patent number: 9358214
    Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
    Type: Grant
    Filed: June 2, 2003
    Date of Patent: June 7, 2016
    Assignee: ADARE Pharmaceuticals, Inc.
    Inventors: Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
  • Hemostatic devices
    Patent number: 9352066
    Abstract: Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: May 31, 2016
    Assignee: Z-MEDICA, LLC
    Inventors: Dina Dubey, Denny Lo
  • Silver containing wound dressing
    Patent number: 9345805
    Abstract: A wound dressing having anti-microbial activity comprises a first fiber capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fiber to which silver (1) cations are bonded and a second fiber which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fiber.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: May 24, 2016
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventor: David Malcolm Woods
  • Controlled-release CNS modulating compositions and methods for the treatment of otic disorders
    Patent number: 9333171
    Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with CNS modulating agent compositions and compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: May 10, 2016
    Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
  • Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof
    Patent number: 9314531
    Abstract: The present invention provides a wound healing composition comprising a biocompatible hydrogel membrane wherein the hydrogel membrane has one or more of the following properties: high water content, high transparency, high permeability, high biocompatibility, high tensile strength and an optimal thickness. The invention further provides methods of treating a wound in a subject in need thereof, comprising contacting the wound with a biocompatible cellulose hydrogel membrane of the invention.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 19, 2016
    Assignee: The Johns Hopkins University
    Inventors: Morgana M. Trexler, Jennifer H. Elisseeff, Daniel Mulreany, Qiongyu Guo, Jennifer L. Breidenich, Jeffrey P. Maranchi, Jenna L. Graham, Julia B. Patrone, Marcia W. Patchan, Xiomara Calderon-Colon
  • Dry powder formulation comprising a phosphodiesterase inhibitor
    Patent number: 9308200
    Abstract: Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 12, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Daniela Cocconi, Francesca Schiaretti, Roberto Bilzi
  • Use of abscisic acid on ornamental plants
    Patent number: 9295253
    Abstract: The present invention describes a method for increasing the drought tolerance of selected ornamental plants comprising administering abscisic acid (ABA) or its salts to said plants.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: March 29, 2016
    Assignee: Valent BioSciences Corporation
    Inventors: Derek D. Woolard, Peter D. Petracek, Craig Campbell